A Phase 2 Study of Elobixibat in Adults With NAFLD or NASH

2期已完成 NCT04006145

适应症	NAFLD, NASH
分期	2期
申办方	Albireo
状态	已完成
受试者人数	47 人
干预（药物）	Elobixibat, Placebo oral tablet
开始日期	2019年6月6日
完成日期	2020年6月26日
结果公布日	2021年9月27日

摘要

Double-blind, randomized, placebo-controlled study to explore the efficacy and safety of elobixibat compared to placebo in adults with NAFLD (nonalcoholic fatty liver disease) or NASH (nonalcoholic steatohepatitis)

Change From Baseline in Serum Low Density Lipoprotein-cholesterol (LDL-C) at Week 16

Week 16 · "mmol/L"

Elobixibat	-0.57 ± 0.125 "mmol/L"
Placebo	-0.17 ± 0.134 "mmol/L"

p-value	0.029
LS-Means Difference	-0.40 (95% CI -0.76–-0.04)

在 BENITIONS 中查看查看 ClinicalTrials.gov 原文

同一适应症的其他试验

A Study of Efruxifermin in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatoh — Akero Therapeutics, Inc
Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Va — Galectin Therapeutics Inc.
Iron Reduction for the Treatment of Diabetes and Nonalcoholic Fatty Liver Disease — Wake Forest University Health Sciences
Effect of Obesity on Proton Pump Inhibitors — Children's Mercy Hospital Kansas City
Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatoti — Merck Sharp & Dohme LLC
Phase 2a Study of HPG1860 in Subjects With NASH — Hepagene (Shanghai) Co., Ltd.

全部试验

本页整理自 ClinicalTrials.gov 的公开数据，不构成医疗建议，也不构成投资建议。请务必咨询专业医师。

English 한국어 日本語中文 Русский